The widely used chemotherapy cisplatin causes permanent hearing loss in 40%–60% of
patients with cancer. One drug, sodium thiosulfate, is approved by the FDA for use in …

Hearing loss caused by noise, aging, antibiotics, and chemotherapy affects 10% of the world
population, yet there are no Food and Drug Administration (FDA)-approved drugs to prevent …

Cisplatin-induced ototoxicity results in significant, permanent hearing loss in pediatric and
adult cancer survivors. Elucidating the mechanisms underlying cisplatin-induced hearing …

Hearing loss is a major disability in everyday life and therapeutic interventions to protect
hearing would benefit a large portion of the world population. Here we found that mice …

Cisplatin is a highly effective treatment for malignant cancers and has become a cornerstone
in chemotherapeutic regimens. Unfortunately, its use in the clinic is often coupled with a high …

Cisplatin is widely used for the treatment of a number of solid malignant tumors. However,
ototoxicity induced by cisplatin is an obstacle to effective treatment of tumors. The basis for …

Evidence of significant hearing loss during the early days of use of cisplatin as a
chemotherapeutic agent in cancer patients has stimulated research into the causes and …

AIM: To investigate a novel pharmacological intervention to mitigate cisplatin ototoxicity
using a selective adenosine A1 receptor agonist adenosine amine congener (ADAC) …

Background Cisplatin-induced ototoxicity affects a high percentage of new cancer patients
worldwide. The detailed mechanism of cisplatin-induced ototoxicity is not completely …

There are currently no FDA-approved therapies to prevent the hearing loss associated with
the usage of cisplatin in chemotherapeutic regimens. We recently demonstrated that the …